Palmitoylethanolamide/Baicalin Supplementation and Changes in Pain and Sudomotor Function in Type 2 Diabetes: A Retrospective Matched Real-World Cohort Study
Observational studyHumansWith baicalin
This study tested palmitoylethanolamide together with baicalin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Observational study
- Subjects
- 96 patients with type 2 diabetes and nerve damage, in two matched groups of 48
- Dose used in the study
- 600 mg of palmitoylethanolamide with 250 mg of baicalin, twice a day (Neuridase). The comparison group took no supplement.
- Duration
- 6 months
- What was measured
- Nerve pain on a visual analogue scale and a skin conductance test of small nerve function
What the authors reported
The authors reported that the median pain score fell from 5.5 to 3.0 in the supplement group (p < 0.0001) and did not change in the comparison group, which started at 2.0. Skin conductance in the hands improved in the supplement group and declined in the comparison group.
Limits of this study
A retrospective study of patient records. The groups differed at the start: the supplement group had much higher pain scores, so regression to the mean cannot be excluded, as the authors state. They also name confounding, a single centre and expectation bias. The publication fee was paid by the product's manufacturer, Enfarma.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.